![](/img/cover-not-exists.png)
Combination Therapy of Imatinib Mesylate and Interferon-α Demonstrates Minimal Activity and Significant Toxicity in Metastatic Renal Cell Carcinoma: Results of a Single-Institution Phase II Trial
Blase N. Polite, Apurva A. Desai, Beth Manchen, Walter M. StadlerVolume:
4
Year:
2006
Language:
english
Pages:
6
DOI:
10.3816/cgc.2006.n.007
File:
PDF, 502 KB
english, 2006